zoledronic acid has been researched along with Cognition Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arden, NK; Cooper, C; Javaid, MK; Judge, A; Lyles, KW; Prieto-Alhambra, D | 1 |
| Barone, A; Foppiani, L; Palummeri, E; Prete, C; Senesi, B; Trasciatti, S; Veneziano, M | 1 |
1 review(s) available for zoledronic acid and Cognition Disorders
| Article | Year |
|---|---|
Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman.
Topics: Aged; Aged, 80 and over; Bone Diseases, Metabolic; Cognition Disorders; Diphosphonates; Disease Progression; Diuretics; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Nervous System Diseases; Sodium Chloride; Treatment Outcome; Zoledronic Acid | 2005 |
1 trial(s) available for zoledronic acid and Cognition Disorders
| Article | Year |
|---|---|
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cognition Disorders; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Psychiatric Status Rating Scales; Secondary Prevention; Treatment Outcome; Zoledronic Acid | 2014 |